Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on MaxCyte (GB:MXCT – Research Report), Kura Oncology (KURA – Research Report) and InMode (INMD – Research Report).
MaxCyte (GB:MXCT)
In a report issued on January 17, Matt Hewitt from Craig-Hallum assigned a Buy rating to MaxCyte. The company’s shares closed yesterday at p410.00.
According to TipRanks.com, Hewitt is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on MaxCyte is a Strong Buy with an average price target of p655.80, which is a 60.0% upside from current levels. In a report issued on January 8, TD Cowen also maintained a Buy rating on the stock with a price target.
See the top stocks recommended by analysts >>
Kura Oncology (KURA)
In a report issued on January 16, Peter Lawson from Barclays assigned a Buy rating to Kura Oncology, with a price target of $30.00. The company’s shares closed last Monday at $14.00.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
Currently, the analyst consensus on Kura Oncology is a Strong Buy with an average price target of $28.32, representing a 91.5% upside. In a report issued on January 2, Brookline Capital Markets also maintained a Buy rating on the stock with a $36.00 price target.
InMode (INMD)
Needham analyst Michael Matson maintained a Hold rating on InMode on January 16. The company’s shares closed last Monday at $23.07, close to its 52-week low of $18.57.
According to TipRanks.com, Matson is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for InMode with a $30.50 average price target, implying a 34.4% upside from current levels. In a report issued on January 16, Canaccord Genuity also maintained a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GB:MXCT:
- MaxCyte jumps 13% to $5.19 after above-consensus Q4 pre-announcement
- MaxCyte sees FY23 revenue $41.1M-$41.3M, consensus $36.72MM
- MaxCyte sees Q4 revenue $15.5M-$15.7M, consensus $10.74M
- MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
- MaxCyte, Lion TCR announces the signing of a strategic platform license
